| Trial ID # | NCT01611558 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/CTLA-4 |
| Drug Name | Ipilimumab |
| Alternate Drug Names | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy |
| Drugs in Trial | Ipilimumab |
| Eligible Participant | Platinum sensitive recurrence and PR, SD or PD in most recent chemotherapy, ≤ 4 prior therapies |
| Patients Enrolled | 49 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, evaluated per RECIST |
| Efficacy | ORR: 10.3% (n=39) |
| Clinically Significant Adverse Events | Serious AE: 45% |
| Conclusion | Encouraging anti-tumor activity, but serious side effects observed |
| Reference | ClinicalTrials.gov, NCT01611558 |